These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28095712)

  • 21. Improved outlook on HIV-1 prevention and vaccine development.
    Vasan S; Michael NL
    Expert Opin Biol Ther; 2012 Aug; 12(8):983-94. PubMed ID: 22583109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward an antibody-based HIV-1 vaccine.
    Hoxie JA
    Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons learned from human HIV vaccine trials.
    Pollara J; Easterhoff D; Fouda GG
    Curr Opin HIV AIDS; 2017 May; 12(3):216-221. PubMed ID: 28230655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
    Moore PL; Williamson C; Morris L
    Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is developing an HIV-1 vaccine possible?
    Haynes BF; Liao HX; Tomaras GD
    Curr Opin HIV AIDS; 2010 Sep; 5(5):362-7. PubMed ID: 20978375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in HIV-1 vaccine development.
    Haynes BF; McElrath MJ
    Curr Opin HIV AIDS; 2013 Jul; 8(4):326-32. PubMed ID: 23743722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals.
    Mayr L; Su B; Moog C
    Curr Opin HIV AIDS; 2017 May; 12(3):209-215. PubMed ID: 28422785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress in HIV-1 vaccine development.
    Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
    J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
    Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
    J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing boosting immunogens for HIV-1 vaccine development.
    Liu Q
    Cell Host Microbe; 2024 May; 32(5):632-634. PubMed ID: 38723601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antibody response in HIV-1-infected donors.
    Richardson SI; Moore PL
    Curr Opin HIV AIDS; 2019 Jul; 14(4):233-239. PubMed ID: 31033730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No acquisition: a new ambition for HIV vaccine development?
    Lakhashe SK; Silvestri G; Ruprecht RM
    Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systems serology for evaluation of HIV vaccine trials.
    Ackerman ME; Barouch DH; Alter G
    Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
    Srivastava IK; Ulmer JB; Barnett SW
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S33-52. PubMed ID: 15285704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The changing face of HIV vaccine research.
    Kwong PD; Mascola JR; Nabel GJ
    J Int AIDS Soc; 2012 Jul; 15(2):17407. PubMed ID: 22789610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies.
    Seddiki N; Lévy Y
    Curr Opin HIV AIDS; 2018 Mar; 13(2):119-127. PubMed ID: 29329113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.